Outpatient Administration of Blinatumomab Infusion and Hematopoietic
Stem Cell Transplantation as Treatment for Patients with Refractory
Acute Lymphoblastic Leukemia in a Pediatric Oncologic Center in Mexico.
Abstract
Acute Lymphoblastic Leukemia (ALL) is the most common pediatric cancer
and the most common subtype of pediatric leukemia, the high toxicity,
relapse and refractory disease of many patients require the development
of novel therapeutic approaches. New therapeutic approaches such as
targeted immunotherapy in combination with Hematopoietic Stem Cell
Transplantation (HSCT) must be taken in count to revolutionize the
management of numerous ALL subtypes, improve treatment outcomes and
maintain low toxicity without losing the effectiveness of the treatment.
We evaluated a novel therapeutic approach in Mexico, the outpatient
administration of blinatumomab infusion in patients with
relapsed/refractory acute lymphoblastic leukemia (R/R ALL).